Spinnaker Etf Series North Shor (NYSE:KOOL)

WEB NEWS

Thursday, February 10, 2011

Comments & Business Outlook
“The major story for us in the 2011 second quarter is our exciting development in China. We believe the Chinese cord blood market could equal or exceed the size of the U.S. market in the next 2-3 years. We also believe we have a ‘first mover advantage’ in China. Our previously-announced agreement with Nanshan also bodes well for us as we begin the process to distribute our bone marrow line of products in China.  Our exclusive distribution partner in China consented to the direct sales to Beike and will receive a small royalty in return. We believe we have developed the strongest partners and channels into the Chinese regenerative medicine market of any cell separation equipment provider.  Successes experienced in China should be mirrored in other Asian countries, as well,” Engle added.


Market Data powered by QuoteMedia. Terms of Use